October 21, 2024
2 min watch
Save
VIDEO: Dose expansion study performed on novel BCL-2 inhibitor for acute myeloid leukemia
In this video, Noah Merin, MD, PhD, discusses the results of a Chinese study into the use of venetoclax in the treatment of acute myeloid leukemia and non-Hodgkin lymphoma, presented at ESMO Congress.
Merin, director of the leukemia program at Cedars-Sinai Medical Center, highlighted the study, which was a dose escalation expansion study of a class of drug that AML has already displayed responsiveness to.
“[TQB3909] looks like a plausible member of the BCL 2 class,” Merin said.
Reference:
- Qi J, et al. Abstract 800MO. Presented at European Society for Medical Oncology Congress; Sept. 13-17; Barcelona, Spain.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Merin reports no relevant financial disclosures.
Read more about